Allina Health Cancer Institute - Abbott Northwestern Hospital

Clinical research site in Minneapolis, Minnesota · Allina Health Cancer Institute – Minneapolis, 913 E 26th St STE 401, Minneapolis, MN 55407 · (612) 863-0200 · Website

Part of Allina Health Cancer Institute

As of July 2026, 12 paid clinical trials are recruiting at Allina Health Cancer Institute - Abbott Northwestern Hospital in Minneapolis, Minnesota. Active studies at this site cover conditions such as Advanced Hepatocellular Carcinoma, Breast Cancer and Carcinoma, Hepatocellular. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Allina Health Cancer Institute - Abbott Northwestern Hospital (12)

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

for Carcinoma, Hepatocellular

29 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227012·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

133 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

45 locations incl. Little Rock

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

for Non-small Cell Lung Cancer

17 locations incl. Little Rock

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06422143·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for Non-small Cell Lung Cancer (NSCLC)

10 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06170788·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

for Brain Cancer

16 locations incl. Duarte

Sponsor: Adela, Inc

Sex: All·Age: 40+·Accepts healthy volunteers

Code: NCT05366881·Recruiting·Listed May 2022

Apply to this trial

More research sites in Minneapolis

University of Minnesota (308 trials)
Abbott-Northwestern Hospital (85 trials)
Hennepin County Medical Center (74 trials)
University of Minnesota/Masonic Cancer Center (39 trials)
Minneapolis Heart Institute Foundation (31 trials)
Children's Hospitals and Clinics of Minnesota - Minneapolis (27 trials)
Minneapolis VA Health Care System, Minneapolis, MN (27 trials)
Health Partners Inc (26 trials)
Masonic Cancer Center (15 trials)
Minneapolis Heart Institute (14 trials)

Explore more

Paid clinical trials in Minneapolis, MN · Minnesota clinical trials